Key Takeaways:
- Hepion Pharmaceuticals (HEPA, Financial) calls off its merger with Pharma Two B without penalties.
- Wall Street analysts predict a significant upside potential for HEPA stock.
- Current brokerage recommendation deems HEPA as "Outperform."
Hepion Pharmaceuticals Cancels Merger
In a strategic pivot, Hepion Pharmaceuticals (HEPA) has decided to terminate its merger agreement with Pharma Two B. This decision, initially announced in July 2024, has been mutually agreed upon by both companies without incurring any financial penalties. As a result, Hepion has also canceled the stockholder meeting originally scheduled for December 12, 2024.
Wall Street Analysts Forecast
Hepion Pharmaceuticals Inc (HEPA, Financial) has caught the attention of analysts, with a one-year price target averaging $30.00. This projection, based on assessments from one analyst, implies a staggering upside of 7,217.07% from the current trading price of $0.41. Both the high and low estimates are aligned at $30.00. For a deeper dive into these projections, visit the Hepion Pharmaceuticals Inc (HEPA) Forecast page.
Current consensus from one brokerage firm places Hepion Pharmaceuticals Inc's (HEPA, Financial) average brokerage recommendation at 2.0, signaling an "Outperform" status. This rating is part of a scale from 1 to 5, where 1 represents a Strong Buy and 5 signifies a Sell.
